Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain

NCT01264237 is registered in ClinicalTrials.gov with Analgesic Solutions as lead sponsor.

NCT NCT01264237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01264237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain
Lead sponsor
Analgesic Solutions
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2011
Completion date
April 30, 2012
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuralgia, postherpetic neuralgia